Making waves with new directions – there are many possible ways to go when considering targeting the adenosine axis
As we segue between our AACR and ASCO coverage, one topic that straddles both virtual meetings is targeting the adenosine axis. At AACR19, this pathway was very much front and square with some intriguing and controversial data presented, which caught many people by surprise.
Since then, several companies have opened new trials, others are completing enrollment and waiting for their data to readout before deciding upon next steps.
It’s a good time to take a look at what’s new in this niche and also see things differently through the lens of one company involved in the field. Yes, it’s time to share our latest expert interview from not one, but two, c-suite executives.
What are their perspectives (they are different), where do they see the field going and why?
In part one of the discussion we focus exclusively on adenosine targeting and how they see themselves differentiated from the crowd… it certainly makes for interesting reading!
To learn more from our oncology analysis and get a heads up on insights and commentary on the adenosine axis subscribers can log-in or you can click to gain access to BSB Premium Content.
The huge pile of interesting scientific papers yet to be read seems to breed overnight and one constantly feels like they’re 2,000 articles behind, even with spending Friday mornings attacking them with gusto.
This was as true in my PhD days as it is now. For a scientist, these represent a lifeline and an important necessity, rather than a luxury.
In the last journal club posting we covered some hot topics in cancer immunotherapy, so this one covers a very different topic, namely targeted therapies.
It’s a good time for a new journal club post, where we tackle some of the recent published literature in oncology and highlight some important new findings that could have an impact on cancer research and development.
Subscribers can log-in to learn more…
The potential of Clovis Oncology’s EGFR inhibitor rociletinib (formerly CO-1686) to treat T790M negative non-small cell lung cancer (NSCLC) was one of the interesting talking points of the recent JP Morgan Healthcare conference in San Francisco (JPM15).
At the JP Morgan Healthcare Conference (JPM15), Clovis presented updated data that shows some efficacy in those NSCLC patients who no longer respond to an EGFR inhibitor, but don’t have a T790M mutation (T790M negative). Both AstraZeneca’s competitor compound, AZD9291, and rociletinib shown considerable activity in those EFGR resistant patients who develop a T790M mutation and it’s likely they will both soon be approved in this indication, based on the encouraging data seen to date.
However, what is surprising and could be a key differentiation factor for Clovis, is if there is sufficient efficacy in T790M negative patients for use of the drug in this indication.
In this post, we discuss the potential of rociletinib in NSCLC T790M negative patients, whether thought leaders might use the drug in this indication, and delve deeper into the science behind the efficacy seen.
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.